Teva is developing compound for type 1 diabetes

12/19/2011 | Bloomberg

Teva Pharmaceutical Industries plans to use the DiaPep277 compound to develop a treatment that would replace insulin therapy in some patients with type 1 diabetes. In a trial, the drug appeared to promote stable C-peptide levels, an indication of insulin secretion by pancreatic cells, researchers said. The results of a second late-stage trial are expected in 2014.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA